Sodium 5-(1,5-dimethyl-1H-pyrazol-4-yl)-isoxazole-3-carboxylate
CAS: 1147201-50-0
Ref. 3D-XVB20150
| 1g | A consultar | ||
| 5g | A consultar |
Informação sobre produto
Sodium 5-(1,5-dimethyl-1H-pyrazol-4-yl)-isoxazole-3-carboxylate (SNX-111) is a novel, orally active, nonselective inhibitor of the enzyme diacylglycerol acyltransferase 2 (DGAT2). SNX-111 is in development for the treatment of lipid metabolism disorders and as an adjunct to diet and exercise. In a study of patients with hyperlipidaemia and type 2 diabetes mellitus, SNX-111 was found to reduce serum triglycerides and cholesterol levels. SNX-111 also reduced blood sugar levels in diabetic patients with elevated blood sugar levels.
SNX-111 has been shown to be well tolerated in short term clinical trials for up to 12 weeks. The most common side effects were headache, diarrhoea, nausea, vomiting and abdominal pain.
Propriedades químicas
Consulta técnica sobre: 3D-XVB20150 Sodium 5-(1,5-dimethyl-1H-pyrazol-4-yl)-isoxazole-3-carboxylate
Se desejar solicitar um orçamento ou fazer uma encomenda, por favor, adicione os produtos ao seu carrinho e depois solicite um orçamento ou encomenda a partir do carrinho. É mais rápido, mais barato e poderá beneficiar-se dos descontos e outras vantagens disponíveis.
